Erschienen in:
01.02.2012 | HSS Osteoarthritis Symposium: Frontiers in OA
Patient Evaluation and OA Study Design: OARSI/Biomarker Qualification
verfasst von:
Virginia Byers Kraus, MD, PhD
Erschienen in:
HSS Journal ®
|
Ausgabe 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Qualification is defined as the “graded, ‘fit-for-purpose’ evidentiary process linking a biomarker with biology and clinical endpoints” [
5]. As recently defined by the Federal Drug Administration (FDA), “qualification is a conclusion that within the stated context (manner and purpose) of use, the results of assessment with a drug development tool (DDT) can be relied upon to have a specific interpretation and application in drug development and regulatory decision making” [
3]. …